New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
10:00 EDTARG, HTZ, BBBY, RBA, TITN, WSO, UN, TMK, TAM, SPH, STCK, SJR, REGN, PL, MHFI, PETM, XONE, CRUS, APOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Airgas (ARG) downgraded to Sell from Neutral at Goldman... Cirrus Logic (CRUS) downgraded to Underperform from Sector Perform at Pacific Crest... ExOne (XONE) downgraded to Hold from Buy at Canaccord... McGraw Hill Financial (MHFI) downgraded to Hold from Buy at Benchmark Co... PetSmart (PETM) downgraded to Neutral from Buy at UBS... Protective Life (PL) downgraded to Market Perform from Outperform at Raymond James... Regeneron (REGN) downgraded to Market Perform from Outperform at BMO Capital... Shaw Communications (SJR) downgraded to Neutral from Buy at BofA/Merrill... Stock Building Supply (STCK) downgraded to Neutral from Buy at Goldman... Suburban Propane (SPH) downgraded to Sell from Neutral at Goldman... Taminco (TAM) downgraded to Neutral from Buy at Goldman... Torchmark (TMK) downgraded to Underperform from Market Perform at Raymond James... Unilever (UN) downgraded to Underweight from Neutral at JPMorgan... Watsco (WSO) downgraded to Sell from Neutral at Goldman... Titan Machinery (TITN) downgraded to Sell from Hold at Cantor... Ritchie Bros. (RBA) downgraded to Sell from Hold at Cantor... Bed Bath & Beyond (BBBY) downgraded to Neutral from Buy at Gilford Securities... Hertz (HTZ) downgraded to Neutral from Buy at Goldman... Apollo Global (APO) downgraded to Perform from Outperform at Oppenheimer.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 23, 2014
07:31 EDTWSOWatsco reports Q3 EPS $1.56, consensus $1.56
Subscribe for More Information
06:16 EDTPETMPetSmart attracts interest from KKR, NY Post reports
Subscribe for More Information
October 22, 2014
16:10 EDTTMKTorchmark reports Q3 EPS 99c, consensus $1.03
Subscribe for More Information
15:30 EDTTMKNotable companies reporting after market close
Subscribe for More Information
10:09 EDTXONEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:06 EDTBBBYBed Bath & Beyond management to meet with Deutsche Bank
Field trip to company headquarters to be held in Union, NJ on October 22 hosted by Deutsche Bank.
October 21, 2014
16:18 EDTXONEExOne initiated with an Outperform at Oppenheimer
Subscribe for More Information
14:09 EDTHTZThird Point discloses new positions in eBay, Alibaba, exit from Sony
In its Q3 investor letter, Third Point says it established a "significant" position in eBay (EBAY). Dan Loeb's hedge fund also revealed it has established a significant direct investment in Alibaba (BABA) shares now that the company is public. Third Point also said it is now one of Amgen's (AMGN) largest shareholders. During the quarter, Third Point exited its position in Sony (SNE) and reduced or exited other positions, including AIG (AIG), Hertz (HTZ) and Softbank (SFTBF), the firm stated in its letter. PRICE ACTION: Following the disclosures in the Third Point letter, Amgen is up 4%, eBay is up 2.3% and Alibaba is up 3.8%, while Sony shares trading in New York are down nearly 1%.
14:04 EDTCRUSEarnings Preview: Analysts divided on Broadcom ahead of Q3 report
Subscribe for More Information
11:02 EDTHTZHertz, United Airlines upgrade partnership
Subscribe for More Information
08:12 EDTHTZNissan selects Hertz as exclusive mobility partner
Subscribe for More Information
October 20, 2014
18:51 EDTCRUSOn The Fly: After Hours Movers
Subscribe for More Information
18:22 EDTCRUSSkyworks Solutions, Cirrus Logic, others higher after Apple reports Q4 results
The following stocks are moving higher in the after hours following Apple's Q4 results: ARM Holdings (ARMH) is up 1.1%, Skyworks Solutions (SWKS) is higher by 2.2% ,NXP Semiconductors (NXPI), up 2.28%,Cirrus Logic (CRUS) is up 2%, RF Micro Devices (RFMD) gains 1.53% and Avago Technologies (AVGO) is up 1.17%.
08:58 EDTHTZJana Partners reports 7% stake in Hertz, says may engage in talks
Subscribe for More Information
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
09:31 EDTRBARitchie Bros. downgraded to Mixed from Positive at OTR Global
09:06 EDTREGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
07:07 EDTREGNRegeneron announces EYLEA results from NIH study
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use